Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PTGIR | P43119 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | CHKA | P35790 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13726456 | 0.90 | SIGMAR1 (0.57) | HRH3SIGMAR1ACHESMN1; SMN2KMT2A | |
| SCHEMBL20804352 | 0.85 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2PTGIRCHKA | |
| SCHEMBL1043952 | 0.85 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2PTGIRCHKA | |
| SCHEMBL19285228 | 0.85 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2PTGIRCHKA | |
| SCHEMBL10868711 | 0.85 | SIGMAR1 (0.63) | SIGMAR1ACHESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8320244 | 0.85 | SIGMAR1 (0.63) | HRH3SIGMAR1ACHESMN1; SMN2KMT2A | |
| SCHEMBL1586714 | 0.85 | SIGMAR1 (0.63) | SIGMAR1ACHESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8101249 | 0.85 | SIGMAR1 (0.63) | SIGMAR1ACHESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2390775 | 0.85 | MEN1 (0.68) | HRH3SIGMAR1ACHESMN1; SMN2KMT2A | |
| SCHEMBL12023880 | 0.83 | SIGMAR1 (0.75) | HRH3SIGMAR1ACHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3969458-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2021057696-A1 | HETEROARYL COMPOUND AND APPLICATION THEREOF | 隆泰申医药科技(南京)有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2020232470-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-1833817-B1 | SYNTHESIS OF CCR5 RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-10-13 | — | — | EP | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | disclosed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | disclosed |
| EP-0604494-B1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | AREG, TGFB1, TGFB2 | HRH3 430/4885SIGMAR1 2322/4885ACHE 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.